About Tarix Pharmaceuticals

Tarix Pharmaceuticals is a clinical stage biopharmaceutical company developing peptide drugs to address significant unmet medical needs. These peptides target components of the ACE2/A(1-7)/Mas pathway in the renin angiotensin system (RAS). The Company is focusing on two clinical applications of these peptides, hematopoiesis, including peripheral and cord blood stem cell transplantation, and severe pulmonary disease including pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension.

The Company’s lead product, TXA127, is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 is currently in a multi-center Phase II clinical trial in peripheral blood stem cell transplantation, where it is being evaluated for its ability to enhance engraftment of platelets and white blood cells.  TXA127 is also in two single center clinical trials at M D Anderson, one in cord blood transplantation and the other in myelodysplastic syndrome. In addition, TXA127 is being developed, under grants from the US government, as a treatment for radiation exposure.

Tarix’s second product, PanCyte, is a synthetic, long-acting cyclic analogue of Angiotensin (1-7). PanCyte is in pre-clinical development focused on its use to treat serious pulmonary diseases.